Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799823 | 0.77 | PDE4D (0.57) | PDE4DMAPK1 | |
| SCHEMBL4442028 | 0.77 | PDE4D (0.61) | PDE4D | |
| SCHEMBL2801940 | 0.77 | PDE4D (0.61) | PDE4D | |
| SCHEMBL2798678 | 0.77 | PDE4D (0.61) | PDE4D | |
| SCHEMBL2801773 | 0.76 | PDE4D (0.60) | PDE4DALDH1A1 | |
| SCHEMBL2799859 | 0.76 | PDE4D (0.60) | PDE4DALDH1A1 | |
| SCHEMBL4438899 | 0.76 | PDE4D (0.60) | PDE4DALDH1A1 | |
| SCHEMBL11663631 | 0.75 | DDB1 (0.43) | DDB1CRBNSLC6A3 | |
| SCHEMBL2798432 | 0.74 | PDE4D (0.83) | PDE4DMAPK1ALDH1A1KMT2A | |
| SCHEMBL2801312 | 0.74 | PDE4D (0.83) | PDE4DMAPK1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137150-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| EP-2134686-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008110794-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110793-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2004031149-A1 | SUBSTITUTED GAMMA-PHENYL-DELTA-LACTAMS AND USES RELATED THERETO | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | DDB1 3645/4885CRBN 2073/4885PDE4D 1120/4885 |
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | DDB1 3634/4885CRBN 1793/4885PDE4D 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.